Why the study?
Does a low-dose heparin-warfarin prophylactic anticoagulation protocol prevent fatalities from pulmonary embolism in patients undergoing total hip replacement?
Does a low-dose heparin-warfarin prophylactic anticoagulation protocol prevent fatalities from pulmonary embolism in patients undergoing total hip replacement?
A low-dose heparin-warfarin protocol provides effective prophylaxis against fatal pulmonary embolism after total hip replacement, with an acceptable rate of hematoma.
May support heparin-warfarin prophylaxis after THA; leaves open randomized confirmation of net benefit versus bleeding.
The prime therapeutic objective of prophylactic anticoagulation for patients undergoing total hip replacement is to reduce to a minimum fatalities from pulmonary embolism. Our low-dose heparin-warfarin prophylactic anticoagulation protocol affords significant protection in this regard (one fatal pulmonary embolism in 796 cases) without the use of venography or other objective tests to check for deep venous thrombosis and for all patients including those with venous disease or a history of prior thromboembolic disease. The 13.1% hematoma rate (5.0% late major) is a small, nonlethal, and acceptable price to pay for this protection.
No takes yet. Share an insight, caveat, or question.
Goss et al. (1979) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: